Want to see HK:0673 full AI Analyst Report?
China Health Group (0673) AI Stock Analysis
China Health Group
(HKEX:0673)
The score is driven primarily by weak financial performance: persistent losses, sharply negative operating/free cash flow, and past negative equity outweigh the 2026 revenue rebound. Technicals reinforce the risk with a clear downtrend and negative momentum, while valuation offers limited support due to negative earnings and no dividend yield provided.
China Health Group (0673) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 360.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 81.04K
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- -0.05
- Revenue Growth
- 5.52%
- EPS Growth
- 56.54%
- Country
- Hong Kong
- Employees
- 111
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Distribution
China Health Group Business Overview & Revenue Model
Company Description
Serving as an investment holding company, China Health Group Limited engages in a diverse range of operations. Within the People's Republic of China, its core business involves the supply and maintenance of medical equipment and disposables, coupled...
China Health Group Financial Statement Overview
Summary
Financials are the primary weakness: revenue has been highly volatile and materially lower than earlier years despite a large 2026 rebound, while net losses persist every year with extremely weak net margins in 2025–2026. Cash flow quality is poor with operating cash flow negative since 2023 and a very large outflow in 2026, implying the business is not self-funding. The balance sheet shows relatively modest leverage when equity is positive, but equity turned negative in 2025, highlighting fragility.
Income Statement
14Very NegativeBalance Sheet
46NeutralCash Flow
18Very Negative| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.09M | 41.09M | 38.94M | 59.93M | 76.41M | 107.03M |
| Gross Profit | 7.13M | 7.13M | 9.23M | 13.64M | 27.19M | 28.69M |
| EBITDA | -43.37M | -43.34M | -63.71M | -37.42M | -33.04M | -4.38M |
| Net Income | -48.41M | -47.93M | -67.79M | -40.19M | -42.05M | -12.21M |
Balance Sheet | ||||||
| Total Assets | 157.56M | 157.56M | 147.35M | 192.32M | 221.19M | 225.96M |
| Cash, Cash Equivalents and Short-Term Investments | 21.95M | 21.95M | 1.05M | 4.01M | 11.48M | 8.54M |
| Total Debt | 4.59M | 4.59M | 6.50M | 5.66M | 6.04M | 18.47M |
| Total Liabilities | 96.71M | 96.71M | 147.25M | 132.56M | 127.23M | 140.82M |
| Stockholders Equity | 53.27M | 53.27M | -7.66M | 52.04M | 86.33M | 79.58M |
Cash Flow | ||||||
| Free Cash Flow | -86.14M | -86.28M | -8.35M | -7.03M | -9.59M | 31.00M |
| Operating Cash Flow | -85.50M | -85.64M | -6.76M | -6.40M | -8.22M | 31.80M |
| Investing Cash Flow | -653.00K | -653.00K | -1.58M | -301.00K | -5.40M | -35.29M |
| Financing Cash Flow | 104.83M | 104.96M | 8.79M | -1.24M | 27.66M | 12.96M |
China Health Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0673, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.28, below the 50-day MA of 0.29, and below the 200-day MA of 0.48, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 29.96 is Positive, neither overbought nor oversold. The STOCH value of 7.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:0673.
China Health Group Peers Comparison
Overall Rating
HK:219281Outperform
HK:109965Neutral
HK:260758Neutral
HK:228947Neutral- HK:067341Neutral
HK:193126Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2192 | 81Outperform | HKD 4.67B | 11.63 | 7.05% | 4.98% | 6.47% | 8.10% |
| HK:1099 | 65Neutral | HKD 50.52B | 6.11 | 8.33% | 4.88% | 2.78% | 7.71% |
| HK:2607 | 58Neutral | HKD 64.52B | 11.88 | 6.64% | 5.88% | 9.12% | -3.22% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:2289 | 47Neutral | HKD 592.92M | 10.83 | 7.70% | 6.26% | 14.25% | 0.83% |
| HK:0673 | 41Neutral | HKD 360.66M | -5.29 | -273.18% | ― | 5.52% | 56.54% |
| HK:1931 | 26Underperform | HKD 575.63M | -6.46 | -2.60% | ― | -2.55% | -145.60% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:0673 | China Health Group | 0.26 | -0.36 | -58.06% | |
| HK:2607 | Shanghai Pharmaceuticals Holding Co Class H | 11.11 | -0.06 | -0.53% | |
| HK:1099 | Sinopharm Group Co Class H | 16.19 | -2.17 | -11.84% | |
| HK:1931 | IVD Medical Holding Limited | 0.35 | -5.93 | -94.35% | |
| HK:2192 | Medlive Technology Co., Ltd. | 6.30 | -4.03 | -38.99% | |
| HK:2289 | Charmacy Pharmaceutical Co., Ltd. Class H | 5.49 | 0.38 | 7.46% |
China Health Group Corporate Events
China Health Group Revamps Board, Appoints New INED and CFO
China Health Group Limited has reshaped its senior governance structure with the resignation of independent non-executive director Ms. Yang Huimin, who has moved into the role of chief financial controller, signalling a realignment of financial overs...
China Health Group details board and committee structure
China Health Group Limited has announced the current composition of its board of directors, comprising three executive directors, two non-executive directors and three independent non-executive directors. The disclosure highlights the mix of leadersh...
China Health Group Wins Unanimous Shareholder Backing at AGM
China Health Group Limited reported that all resolutions at its annual general meeting held in Shenzhen on 22 September 2026 were approved unanimously by shareholders via poll voting. The company’s audited consolidated financial statements for...
China Health Group Calls AGM to Renew Board Mandates and Seek New Share-Issuance Authority
China Health Group Limited has called its annual general meeting for 22 September 2026 in Shenzhen, where shareholders will review the audited consolidated financial statements for the year ended 31 March 2026 and consider the re-appointment of its e...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026